Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors
30 July 2020 - 9:05PM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced that Wayne A.I.
Frederick, M.D., has been elected to serve on the company’s board
of directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200730005190/en/
Wayne A.I. Frederick, M.D. (Photo:
Business Wire)
Dr. Frederick is the President of Howard University, as well as
the Charles R. Drew Professor in Surgery at Howard University’s
College of Medicine, and a distinguished researcher and practicing
surgeon. Before his appointment as President in 2014, Dr. Frederick
served as Howard’s Provost and Chief Academic Officer. The author
of an extensive body of peer-reviewed articles, book chapters,
abstracts and editorials, he has also received numerous notable
awards for his scholarship and service. Dr. Frederick is a fellow
of the American College of Surgeons and a member of many other
surgical organizations, including the American Surgical
Association.
“As a practicing physician and experienced medical researcher,
coupled with his leadership skills and business acumen, Wayne
brings valuable perspective to Forma at this pivotal time of growth
for our company, particularly as we look to advance our sickle cell
disease program into a Phase 2/3 pivotal trial next year,” said
Peter Wirth, J.D., chairman, board of directors of Forma.
“I am delighted to welcome such an experienced and sickle cell
community-minded director to join us,” said Frank Lee, chief
executive officer and board member of Forma. “With his deep
understanding of patient needs and his personal commitment to the
sickle cell community, Wayne embodies Forma’s mission and
patient-driven culture.”
“I am honored to join the board of a company that is committed
to and passionate about pursuing treatments for rare hematologic
diseases and cancers,” said Dr. Frederick. “As someone who is
living with Sickle Cell, I am personally dedicated to the search
for new and better therapeutics to combat this painful and
debilitating disease. I am inspired by Frank and the team he has so
diligently assembled for this cause.”
Dr. Frederick will serve on the board’s audit committee. In
addition to his board position at Forma, he currently serves as a
board member for Humana, Inc., the United States Chamber of
Commerce and Mutual of America Life Insurance Co.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding the advancement of our sickle cell disease program, our
expectations of the therapeutic benefits related thereto, and our
expectations regarding our new director. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, those risks and
uncertainties related to the advancement of our sickle cell disease
program and other risks identified in our SEC filings, including
our Registration Statement on Form S-1, and subsequent filings with
the SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005190/en/
Media Contact: Kari Watson, +1 781-235-3060 MacDougall
kwatson@macbiocom.com
Investor Contact: Stephanie Ascher, +1 212-362-1200 Stern
Investor Relations stephanie.ascher@sternir.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024